Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

Detalles Bibliográficos
Autores principales: Lally, David R., Loewenstein, Anat, Arnold, Jennifer J., Yang, Yit C., Gedif, Kinfemichael, Best, Catherine, Patel, Hersh, Tadayoni, Ramin, Heier, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219932/
https://www.ncbi.nlm.nih.gov/pubmed/35676464
http://dx.doi.org/10.1038/s41433-022-02130-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219932/
https://www.ncbi.nlm.nih.gov/pubmed/35676464
http://dx.doi.org/10.1038/s41433-022-02130-2

Ejemplares similares